{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:26:33Z","timestamp":1792797993683,"version":"4.5.0"},"reference-count":88,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T00:00:00Z","timestamp":1548892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Clearside Biomedical","id":[{"id":"https:\/\/ror.org\/0250cw529","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Ophthalmologica"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>\n                      Delivery of pharmaceuticals to the posterior segment presents challenges that arise from the anatomy and clearance pharmacokinetics of the eye. Systemic and several local administration options [topical, periocular, intravitreal (\n                      <jats:styled-content style=\"fixed-case\">IVT<\/jats:styled-content>\n                      ) and subretinal] are in clinical use, each with a unique benefit to risk profile shaped by factors including the administered agent, frequency of dosing, achievable pharmaceutical concentrations within posterior segment structures versus elsewhere in the eye or the body, invasiveness of the procedure and the inherent challenges with some administration methods. The use of the\u00a0suprachoroidal space (\n                      <jats:styled-content style=\"fixed-case\">SCS<\/jats:styled-content>\n                      ), which is the region between the sclera and the choroid, is being explored as a potential approach to target pharmacotherapies to the posterior segment via a minimally invasive injection procedure. Preclinical data on agents such as vascular endothelial growth factor inhibitors and triamcinolone acetonide (\n                      <jats:styled-content style=\"fixed-case\">TA<\/jats:styled-content>\n                      ) indicate that administration via suprachoroidal injection results in more posterior distribution of the pharmacologic agent, with higher exposure to the sclera, choroid, retinal pigment epithelium cells and retina, and lesser exposure to the anterior segment, than observed with\n                      <jats:styled-content style=\"fixed-case\">IVT<\/jats:styled-content>\n                      administration. Based in part on these findings, clinical trials have explored the efficacy and safety of suprachoroidal administration of pharmacologic therapies in conditions affecting the posterior segment. Data on a proprietary formulation of\n                      <jats:styled-content style=\"fixed-case\">TA<\/jats:styled-content>\n                      administered by suprachoroidal injection show improvement in anatomic and visual outcomes in subjects with noninfectious uveitis, with the potential to mitigate the known risks of cataract and increased intraocular pressure (\n                      <jats:styled-content style=\"fixed-case\">IOP<\/jats:styled-content>\n                      ) associated with the use of intraocular corticosteroids. Suprachoroidal administration appears to be a promising treatment modality and is also in the early stages of investigation for other possible applications, such as injection of antiglaucoma agents into the anterior\n                      <jats:styled-content style=\"fixed-case\">SCS<\/jats:styled-content>\n                      for long\u2010lasting control of elevated\n                      <jats:styled-content style=\"fixed-case\">IOP<\/jats:styled-content>\n                      , and as a mode of delivery for gene\u2010 or cell\u2010based therapies for retinal disorders.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/aos.14042","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T06:40:35Z","timestamp":1548916835000},"page":"460-472","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Suprachoroidally injected pharmacological agents for the treatment of chorio\u2010retinal diseases: a targeted approach"],"prefix":"10.1111","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1058-0286","authenticated-orcid":false,"given":"Zohar","family":"Habot\u2010Wilner","sequence":"first","affiliation":[{"name":"Division of Ophthalmology Tel Aviv Medical Center Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Noronha","sequence":"additional","affiliation":[{"name":"Clearside Biomedical, Inc. Alpharetta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7756-5091","authenticated-orcid":false,"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[{"name":"Retina Consultants of Houston Houston Texas USA"},{"name":"Blanton Eye Institute Houston Methodist Hospital &amp; Weill Cornell Medical College Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,1,31]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joco.2018.01.006"},{"key":"e_1_2_8_3_1","volume-title":"CPT\u00ae Category III Codes Code Descriptors","author":"American Medical Association","year":"2017"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2016.10"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.03-1110"},{"key":"e_1_2_8_6_1","unstructured":"Avastin[prescribing information] (2016):San Francisco CA:Genentech Inc."},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.15171\/bi.2016.07"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(02)01969-3"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2011.82"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132902"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2017.07.013"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2015.02.021"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2016.02.041"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2016.10.011"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-20377"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-20679"},{"key":"e_1_2_8_17_1","unstructured":"Clearside Biomedical Inc.(2018a):Clearside Biomedical announces SAPPHIRE phase 3 study of combination therapy in retinal vein occlusion did not meet its primary endpoint[news release]. Available at:http:\/\/ir.clearsidebio.com\/node\/8166\/pdf. (Accessed on 5 Nov 2018)."},{"key":"e_1_2_8_18_1","unstructured":"Clearside Biomedical Inc.(2018b):Clearside Biomedical announces positive topline results from phase 2 clinical trial of CLS\u2010TA used with Eylea in patients with diabetic\u00a0macular edema[news release]. Available at:http:\/\/ir.clearsidebio.com\/news-releases\/news-release-details\/clearside-biomedical-announces-positive-topline-results-phase-2. (Accessed on 31 May 2018)."},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2016.12.001"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.93751"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2016.5659"},{"key":"e_1_2_8_22_1","unstructured":"EdelhauserHF PatelSR MeschterC DeanR PowellK&VerhoevenRS(2013):Suprachoroidal microinjection delivers triamcinolone acetonide to therapeutically\u2010relevant posterior ocular structures and limits exposure in the anterior segment. Poster presented at the 2013 Annual Meeting of the Association for Research in Vision and Ophthalmology May 5\u20109 2013 Seattle WA. Poster #B0021."},{"key":"e_1_2_8_23_1","first-page":"5259","article-title":"Intraocular distribution and targeting of triamcinolone acetonide suspension administered into the suprachoroidal space","volume":"55","author":"Edelhauser HF","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1159\/000315158"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1509501"},{"key":"e_1_2_8_26_1","first-page":"1533","article-title":"Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye","volume":"43","author":"Einmahl S","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2013.107"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2007.00897.x"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001243"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/APO.0000000000000194"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.13-11747"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.5.6.14"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.15-16597"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1159\/000345477"},{"key":"e_1_2_8_35_1","unstructured":"Iluvien[prescribing information] (2016):Alpharetta GA:Alimera Sciences Inc."},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(00)00659-0"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412965"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2006.0067"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000000215"},{"key":"e_1_2_8_41_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5693\/djo.01.2014.07.001","article-title":"Retinal tears and rhegmatogenous retinal detachment after intravitreal injections: its prevalence and case reports","volume":"21","author":"Karabag RY","year":"2015","journal-title":"Digit J Ophthalmol"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.06-0670"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.14-14651"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.06.041"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/APO.0000000000000146"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000355"},{"key":"e_1_2_8_47_1","first-page":"2259","article-title":"BCVA changes after suprachoroideal graft of autologous cells in dry AMD","volume":"56","author":"Limoli PG","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.339"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3282f51031"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-013-2495-0"},{"key":"e_1_2_8_51_1","first-page":"695","article-title":"Periocular injection of steroids","volume":"76","author":"Nozik RA","year":"1972","journal-title":"Trans Am Acad Ophthalmol Otolaryngol"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12803"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2006.05.045"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6291"},{"key":"e_1_2_8_55_1","unstructured":"Ozurdex[prescribing information] (2014):Irvine CA:Allergan Inc."},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-010-0271-y"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-9872"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017140"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1159\/000479157"},{"key":"e_1_2_8_60_1","unstructured":"Retisert[prescribing information] (2012):Rochester NY:Bausch & Lomb Inc."},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3182278b0e"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1159\/000220600"},{"key":"e_1_2_8_63_1","first-page":"125","article-title":"Gene expression profile of human trabecular meshwork cells in response to long\u2010term dexamethasone exposure","volume":"12","author":"Rozsa FW","year":"2006","journal-title":"Mol Vis"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31868-8"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1041916"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2013.767353"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2011.02247.x"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60028-2"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2009.233"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.05.021"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.03.033"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12744"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.01.036"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0420.2006.00698.x"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.10.008"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.4081\/eye.2011.e5"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1159\/000336045"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.1990.41"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0048188"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2017.11.020"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1350-9462(98)00035-4"},{"key":"e_1_2_8_82_1","unstructured":"WykoffCC(2017):Durability of suprachoroidal triamcinolone acetonide in combination with aflibercept in the management of retinal vein occlusion: 9\u2010month analysis of the TANZANITE phase 2 trial and extension study. Data presented at the 40th Annual Macula Society Meeting; June 7\u201010 2017;Singapore."},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2018.03.008"},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000000726"},{"key":"e_1_2_8_85_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002279"},{"key":"e_1_2_8_86_1","unstructured":"YehS;PEACHTREE Study Investigators(2018b):Suprachoroidally injected CLS\u2010TA improves visual acuity and macular edema in noninfectious uveitis: results of the Phase 3 PEACHTREE Study. Abstract presented at the 36th Annual Meeting of the American Society of Retina Specialists July 20\u201025 2018 Vancouver BC."},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2013.7288"},{"key":"e_1_2_8_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-4835(02)00323-8"},{"key":"e_1_2_8_89_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-7749"}],"container-title":["Acta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Faos.14042","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aos.14042","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/aos.14042","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aos.14042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T18:20:12Z","timestamp":1694197212000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/aos.14042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,31]]},"references-count":88,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1111\/aos.14042"],"URL":"https:\/\/doi.org\/10.1111\/aos.14042","archive":["Portico"],"relation":{},"ISSN":["1755-375X","1755-3768"],"issn-type":[{"value":"1755-375X","type":"print"},{"value":"1755-3768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,31]]},"assertion":[{"value":"2018-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}